Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lineage Cell Therapeutics, Inc. (GB:0HNF)
LSE:0HNF
Lineage Therap (0HNF) Share Price & Analysis
1 Followers
0HNF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.25 - $1.25
Previous Close$1.25
Volume0.00
Average Volume (3M)N/A
Market Cap
$245.09M
Enterprise Value$211.16M
Total Cash (Recent Filing)$35.49M
Total Debt (Recent Filing)$2.95M
Price to Earnings (P/E)-10.0
BetaN/A
Next Earnings
May 09, 2024EPS Estimate
-$0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding188,533,536
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard Deviation0.22
R-Squared0.22
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)39.63
Price to Sales (P/S)22.55
Price to Cash Flow (P/CF)-10.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue23.61
Enterprise Value/Gross Profit25.52
Enterprise Value/Ebitda-14.16
Forecast
1Y Price Target
$5.40Price Target Upside332.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Lineage Therap News
PremiumStock Analysis & Ideas
These 2 ‘Strong Buy’ Penny Stocks Could Go Boom, Say Analysts
PremiumCompany Announcements
Lineage Cell Therapeutics Announces Early Shareholder Meeting
PremiumCompany Announcements
Lineage Cell Therapeutics Announces New Investment OfferingOptions Prices
Currently, No data available
---
Ownership Overview
75.13% Insiders
6.89% Mutual Funds
6.61% Other Institutional Investors
11.37% Public Companies and
Individual Investors
0HNF FAQ
What was Lineage Cell Therapeutics, Inc.’s price range in the past 12 months?
Lineage Cell Therapeutics, Inc. lowest share price was $1.25 and its highest was $1.25 in the past 12 months.
What is Lineage Cell Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Lineage Cell Therapeutics, Inc.’s upcoming earnings report date?
Lineage Cell Therapeutics, Inc.’s upcoming earnings report date is May 09, 2024 which is in 23 days.
How were Lineage Cell Therapeutics, Inc.’s earnings last quarter?
Lineage Cell Therapeutics, Inc. released its earnings results on Mar 07, 2024. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.043 by $0.013.
Is Lineage Cell Therapeutics, Inc. overvalued?
According to Wall Street analysts Lineage Cell Therapeutics, Inc.’s price is currently Undervalued.
Does Lineage Cell Therapeutics, Inc. pay dividends?
Lineage Cell Therapeutics, Inc. does not currently pay dividends.
What is Lineage Cell Therapeutics, Inc.’s EPS estimate?
Lineage Cell Therapeutics, Inc.’s EPS estimate is -$0.04.
How many shares outstanding does Lineage Cell Therapeutics, Inc. have?
Lineage Cell Therapeutics, Inc. has 188,533,540 shares outstanding.
What happened to Lineage Cell Therapeutics, Inc.’s price movement after its last earnings report?
Lineage Cell Therapeutics, Inc. reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.043. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lineage Cell Therapeutics, Inc.?
Among the largest hedge funds holding Lineage Cell Therapeutics, Inc.’s share is Defender Capital, LLC.. It holds Lineage Cell Therapeutics, Inc.’s shares valued at 5M.
---
Lineage Therap Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.40 (332.00% Upside)
$5.40 (332.00% Upside)
Blogger Sentiment
Bullish
GB:0HNF Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $7.1M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.14%
12-Months-Change
Fundamentals
Return on Equity
-31.42%
Trailing 12-Months
Asset Growth
-18.31%
Trailing 12-Months
Company Description
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.
---
0HNF Earnings Call
Q4 2024
0:00 / 0:00
---
0HNF Stock 12 Months Forecast
Average Price Target
$5.40
▲(332.00% Upside)
Technical Analysis
Lineage Therap
―
Advaxis
―
Citius Pharmaceuticals
―
Fate Therapeutics
―
Traws Pharma
―
Best Analysts Covering 0HNF
1 Year
1 Year Success Rate
6/16 ratings generated profit
1 Year Average Return
-1.61%
reiterated a buy rating last month
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -1.61% per trade.
---